NEBIVOLOL

Details

Stereochemistry	RACEMIC
Molecular Formula	C22H25F2NO4
Molecular Weight	405.435
Optical Activity	( + / - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

O[C@H](CNC[C@@H](O)[C@@H]1CCC2=C(O1)C=CC(F)=C2)[C@H]3CCC4=CC(F)=CC=C4O3

InChI

InChIKey=KOHIRBRYDXPAMZ-YHBROIRLSA-N

InChI=1S/C22H25F2NO4/c23-15-3-7-19-13(9-15)1-5-21(28-19)17(26)11-25-12-18(27)22-6-2-14-10-16(24)4-8-20(14)29-22/h3-4,7-10,17-18,21-22,25-27H,1-2,5-6,11-12H2/t17-,18-,21-,22+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C22H25F2NO4
Molecular Weight	405.435
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	4 / 4
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | https://www.ncbi.nlm.nih.gov/pubmed/18485134 | https://www.ncbi.nlm.nih.gov/pubmed/9825177 | https://www.ncbi.nlm.nih.gov/pubmed/21283024 | https://www.ncbi.nlm.nih.gov/pubmed/1681809 | https://www.ncbi.nlm.nih.gov/pubmed/1357130https://www.drugbank.ca/drugs/DB04861 | https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_LBL.pdf | http://www.bystolic.com/

Nebivolol is a competitive and highly selective beta-1 receptor antagonist with mild vasodilating properties, possibly due to an interaction with the L-arginine/nitric oxide pathway. In preclinical studies, nebivolol has been shown to induce endothelium-dependent arterial relaxation in a dose dependent manner, by stimulation of the release of endothelial nitric oxide. Nitric oxide acts to relax vascular smooth muscle cells and inhibits platelet aggregation and adhesion. Activation of β1-receptors by epinephrine increases the heart rate and the blood pressure, and the heart consumes more oxygen. Nebivolol blocks these receptors which reverses the effects of epinephrine, lowering the heart rate and blood pressure. In addition, beta blockers prevent the release of renin, which is a hormone produced by the kidneys which leads to constriction of blood vessels. At high enough concentrations, this drug may also bind beta 2 receptors. Marketed under the brand name BYSTOLIC, Nebivolol is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-1 adrenergic receptor 163 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/2455841 \| https://www.ncbi.nlm.nih.gov/pubmed/2462161 \| https://www.allergan.com/assets/pdf/bystolic_pi \| https://www.ncbi.nlm.nih.gov/pubmed/11309254	Antagonist 2849		0.7 nM [Ki]
Beta-1 adrenergic receptor 163 Target ID: CHEMBL213 Sources: https://www.ncbi.nlm.nih.gov/pubmed/21283024 \| https://www.ncbi.nlm.nih.gov/pubmed/1681809	Antagonist 2849		0.35 nM [IC50]

Conditions

Condition	Modality	Targets	Highest Phase	Product
Hypertension 575 Sources: https://www.allergan.com/assets/pdf/bystolic_pi https://www.drugs.com/pro/nebivolol.html https://www.ncbi.nlm.nih.gov/pubmed/19393838	Primary		Approved 8583	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 2007
Hypertension 575 Sources: https://www.ncbi.nlm.nih.gov/pubmed/7596131 https://www.ncbi.nlm.nih.gov/pubmed/7692155 https://www.ncbi.nlm.nih.gov/pubmed/18485134 https://www.ncbi.nlm.nih.gov/pubmed/1357130	Primary		Approved 8583	BYSTOLIC Approved Use BYSTOLIC is a beta-adrenergic blocking agent indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. BYSTOLIC may be used alone or in combination with other antihypertensive agents . Launch Date 2007

C_max

Value	Dose	Co-administered	Analyte	Population
1.48 ng/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

AUC

Value	Dose	Co-administered	Analyte	Population
7.76 ng × h/mL REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

T_1/2

Value	Dose	Co-administered	Analyte	Population
11 h REVIEW https://pubmed.ncbi.nlm.nih.gov/18083889/	10 mg single, oral dose: 10 mg route of administration: Oral experiment type: SINGLE co-administered:		NEBIVOLOL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

F_unbound

Value	Dose	Co-administered	Analyte	Population
2% DRUG LABEL https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unknown		NEBIVOLOL plasma	Homo sapiens population: UNKNOWN age: UNKNOWN sex: UNKNOWN food status: UNKNOWN

Doses

Dose	Population	Adverse events
500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	Disc. AE: Hyperhidrosis, Pallor... AEs leading to discontinuation/dose reduction: Hyperhidrosis Pallor Depressed level of consciousness Hypokinesia Hypotension Sinus bradycardia Hypoglycemia Hypokalemia Respiratory failure Vomiting Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (0.4%) Nausea (0.2%) Bradycardia (0.2%) Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf	Disc. AE: Disorder fetal... AEs leading to discontinuation/dose reduction: Disorder fetal Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf

AEs

AE	Significance	Dose	Population
Depressed level of consciousness	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Hyperhidrosis	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Hypoglycemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Hypokalemia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Hypokinesia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Hypotension	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Pallor	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Respiratory failure	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Sinus bradycardia	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Vomiting	Disc. AE	500 mg single, oral Overdose Dose: 500 mg Route: oral Route: single Dose: 500 mg Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	healthy Health Status: healthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Bradycardia	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Nausea	0.2% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Headache	0.4% Disc. AE	40 mg 1 times / day multiple, oral Recommended Dose: 40 mg, 1 times / day Route: oral Route: multiple Dose: 40 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021742s022lbl.pdf
Disorder fetal	Disc. AE	5 mg 1 times / day multiple, oral Recommended Dose: 5 mg, 1 times / day Route: oral Route: multiple Dose: 5 mg, 1 times / day Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf	unhealthy Health Status: unhealthy Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/206302s000lbl.pdf

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946	inhibitor 2438	substrate 1388 inhibitor 2507

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2B6 926 CYP2C8 1057 CYP2C19 2057 CYP3A4/5 296

Drug as perpetrator

Target	Modality	Activity
CYP1A2 2333	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2A6 911	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2B6 1160	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C19 2141	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C8 1117	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2C9 2497	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP2D6 2546	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no
CYP3A4/5 357	inhibitor 4027 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 50, 55	no

Drug as victim

Target	Modality	Activity	Metabolite	Clinical evidence
CYP3A4 1946	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2007/021742s000_ClinPharmR_P1.pdf Page: 28, 50, 55	minor
CYP2D6 1388	substrate 4014 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0	yes		yes (co-administration study) Comment: from product label: fluoxetine coadministration led to increased AUC by 8% and Cmax by 3-fold Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/206302Orig1s000ClinPharmR.pdf Page: 17.0

Sourcing

Vendor/Aggregator	ID	URL
AChemBlock	10241
AK Scientific	M753
Aronis	BBC/719
BOC Sciences	118457-15-1
eMolecules	29703203
eMolecules	300435536
eMolecules	30387256
IBScreen	BB_SC-12513
IBScreen	Bio-0068
Lab Network	LN01346236
mcule	MCULE-7932280679
MolPort	MolPort-003-849-342
MolPort	MolPort-023-276-830
ShangHai Biochempartner	BCP21038
Tocris	3517
Toronto Research Chemicals	N387896
Vitas-M Laboratory	STK637549
ZINC	ZINC000003951631	http://zinc15.docking.org/substances/ZINC000003951631

PubMed

Title	Date	PubMed
Different pharmacological properties of two enantiomers in a unique beta-blocker, nebivolol.	2008	18485134
[Genetic polymorphisms in drug metabolizing enzymes--impact on treatment with beta-blockers].	2004-04-08	15054690
Antioxidant activity of nebivolol in the rat aorta.	2004-01	14668581
[Nebivolol in the treatment of ischemic heart disease patients with chronic heart failure].	2004	15029131
The shift in the "paradigm" of the pharmacology of hypertension.	2004	14965315
[Beta blocker improves the endothelial function. Gas-forming blood vessel protection].	2003-12-18	14974334
Efficacy and tolerability profile of nebivolol vs atenolol in mild-to-moderate essential hypertension: results of a double-blind randomized multicentre trial.	2003-12	14761075
Nebivolol and its 4-keto derivative increase nitric oxide in endothelial cells by reducing its oxidative inactivation.	2003-11-19	14642697
[Endothelial dysfunction and metabolic effects of nitric oxide in human].	2003-11-13	14611088
[Beta-1 blockade plus NO release. Additional organ protection for patients with hypertension].	2003-10-02	14603611
Beta-blocker treatment of patients with diastolic heart failure and arterial hypertension. A prospective, randomized, comparison of the long-term effects of atenolol vs. nebivolol.	2003-10	14607201
Long-term treatment with nebivolol improves arterial reactivity and reduces ventricular hypertrophy in spontaneously hypertensive rats.	2003-09	12960679
Lack of inverse agonistic activity of nebivolol, its D- and L-enantiomers and of in vivo metabolized nebivolol in human myocardium.	2003-08-22	12969754
Comparison of effects on systolic and diastolic left ventricular function of nebivolol versus atenolol in patients with uncomplicated essential hypertension.	2003-08-01	12888152
Involvement of the beta3 adrenoceptor in nebivolol-induced vasorelaxation in the rat aorta.	2003-08	12883327
Third-generation beta-blockers stimulate nitric oxide release from endothelial cells through ATP efflux: a novel mechanism for antihypertensive action.	2003-06-03	12742996
The combination of nebivolol plus pravastatin is associated with a more beneficial metabolic profile compared to that of atenolol plus pravastatin in hypertensive patients with dyslipidemia: a pilot study.	2003-06	12808486
A comparison of the beta1-selectivity of three beta1-selective beta-blockers.	2003-06	12795776
Different effect of antihypertensive drugs on conduit artery endothelial function.	2003-06	12719441
[Initial data on nebivolol in heart failure. Beta blockers strengthen older hearts, too].	2003-05-29	12866284
Comparative effects of a two-week treatment with nebivolol and nifedipine in hypertensive patients suffering from COPD.	2003-05-28	15031571
Comparison of the new cardioselective beta-blocker nebivolol with bisoprolol in hypertension: the Nebivolol, Bisoprolol Multicenter Study (NEBIS).	2003-05	14574084
Evaluation of the efficacy and tolerability of nebivolol versus lisinopril in the treatment of essential arterial hypertension: a randomized, multicentre, double-blind study.	2003-05	12800985
Effects of nebivolol on ischemia-induced metabolic changes in dog hearts.	2003-05	12717108
Nebivolol prevents vascular NOS III uncoupling in experimental hyperlipidemia and inhibits NADPH oxidase activity in inflammatory cells.	2003-04-01	12692005
[Hemodynamic effects of the beta blocker nebivolol].	2003-04	12914405
Angiotensin-converting enzyme inhibition but not beta-adrenergic blockade limits transforming growth factor-beta overexpression in acute normotensive anti-thy1 glomerulonephritis.	2003-04	12658024
Beta 1-adrenoceptor selectivity of nebivolol and bisoprolol. A comparison of [3H]CGP 12.177 and [125I]iodocyanopindolol binding studies.	2003-01-26	12535855
[Influence of the beta-blocker nebivolol on left ventricular function in patients with chronic heart failure].	2003-01-15	12540987
Effect of forced titration of nebivolol on response rate in obese hypertensive patients.	2003-01	12517695
[Nebivolol effects on platelet aggregation and anticoagulation system].	2003	14603912
[Heart rate control with nebivolol in patients with tachysystolic atrial fibrillation].	2003	14593370
[The use of nebivolol in menopausal women with hypertension].	2003	14593358
[Dynamics of a 24-h profile of arterial pressure and function of the vascular endothelium in nebivolol treatment of hypertensive patients].	2003	14520947
[Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction].	2003	12934313
[Effect of nebivolol on the state of pituitary-gonadal system and lipid peroxidation in young and middle aged men with hypertension].	2003	12891274
[Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes].	2003	12891271
[Use of nebivolol in patients with mild and moderate hypertension].	2003	12718224
[Beta blocker enhances NO liberation in the endothelium. Vascular tone long-term improvement].	2002-12-05	12577747
Gateways to clinical trials.	2002-12	12616965
No-dependent vasodilation induced by nebivolol in coronary circulation is not mediated by beta-adrenoceptors or by 5 HT1A-receptors.	2002-12	12512696
Nebivolol ameliorates nitric oxide deficient hypertension.	2002-06-20	12806161
[Effect of nebivolol on the level of constitutional, inducible, and total NO-synthase in serum of patients with type II diabetes mellitus].	2002	12669563
[Effect of enape combined with nebilet in hypertension].	2002	12587324
[Functional and biochemical characteristics of the vasodilator effects of nebivolol in patients with arterial hypertension].	2002	12577837
[Assessment of efficacy and safety of nebivolol in patients with stable effort angina].	2002	12494203
[Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension].	2002	12494141
Nebivolol: comparison of the effects of dl-nebivolol, d-nebivolol, l-nebivolol, atenolol, and placebo on exercise-induced increases in heart rate and systolic blood pressure.	1998-09	9825177
Effects of D-nebivolol and L-nebivolol on left ventricular systolic and diastolic function: comparison with D-L-nebivolol and atenolol.	1993-08	7692155
Relationship between the sympatholytic action of nebivolol and hypotension.	1992-07	1383620

Patents

Sample Use Guides

In Vivo Use Guide

After a 4-week placebo run-in period, 30 patients (mean age 48 years) were randomly allocated to double-blind treatment with either DL-nebivolol 5 mg or D-nebivolol 2.5 mg once daily for 4 weeks.

Route of Administration: Oral

In Vitro Use Guide

Nebivolol and d-nebivolol (SRRR) inhibited noradrenaline-induced cAMP accumulation with IC50 values of 22 and 15 nM, respectively in rat living cardiac cells.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 18:05:19 GMT 2025` Edited by `admin` on `Mon Mar 31 18:05:19 GMT 2025`
Record UNII	030Y90569U
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

R-65824

Preferred Name

English

NEBIVOLOL

Official Name

English

NEBIVOLOL [VANDF]

Common Name

English

nebivolol [INN]

Common Name

English

NEBIVOLOL [MI]

Common Name

English

NEBIVOLOL [MART.]

Common Name

English

NEBIVOLOL [USAN]

Common Name

English

R65,824

Code

English

Nebivolol [WHO-DD]

Common Name

English

NARBIVOLOL

Common Name

English

BYVALSON COMPONENT NEBIVOLOL

Common Name

English

(±)-Nebivolol

Common Name

English

2H-1-Benzopyran-2-methanol, ?,??-[iminobis(methylene)]bis[6-fluoro-3,4-dihydro-, (?R,??R,2R,2?S)-rel-

Systematic Name

English

rel-(?R,??R,2R,2?S)-?,??-[Iminobis(methylene)]bis[6-fluoro-3,4-dihydro-2H-1-benzopyran-2-methanol]

Systematic Name

English

Classification Tree Code System Code

LIVERTOX

NBK548386